Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

venetoclax 45Specimen Handling 35Azacitidine 34Cytarabine 32Biopsy 23fludarabine 21Cyclophosphamide 16decitabine and cedazuridine drug combination 14Injections 14Daunorubicin 14fludarabine phosphate 12Whole-Body Irradiation 11Mycophenolic Acid 10Busulfan 10Tacrolimus 9Melphalan 9Idarubicin 9CPX-351 9ivosidenib 8Stem Cell Transplantation 8Granulocyte Colony-Stimulating Factor 8Gemtuzumab 7Cyclosporine 7enasidenib 6X-Rays 6Magnetic Resonance Spectroscopy 6Filgrastim 6Decitabine 6olutasidenib 5gilteritinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × Cytochrome P-450 CYP2C8 × 30 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡